Dewpoint Therapeutics Announces an Open IND for First-in-Class Condensate Modulator DPTX3186 for Wnt-Driven Cancers
IND opening marks culmination of partnership between Dewpoint and Evotec, advancing a de novo development candidate through IND-enabling studies First patient dosing planned before year-end 2025 at leading cancer centers in collaboration with top key opinion leaders Program validates Dewpoint's condensate-modulator discovery platform and the value of agile, integrated partnerships in accelerating novel drug development. […]